QIAGEN launches AI-derived biomedical knowledge base to accelerate data-driven drug discovery
28 February 2024 - 9:44AM
QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced
the launch of QIAGEN Biomedical KB-AI, a new generative AI-driven
knowledge base designed to propel drug discovery in the pharma and
biotech industries. This new offering is designed for data
scientists and bioinformaticians who are looking for the most
comprehensive knowledge graphs to fuel data-driven drug discovery.
QIAGEN Biomedical KB-AI is built on a massive
dataset of biomedical literature and other scientific sources. It
identifies and extracts causal relationships between genes,
diseases, drugs and other biological entities with AI, generating
over 600 million more biomedical relationships than its complement,
QIAGEN Biomedical KB-HD. This expansive knowledge base helps data
scientists understand disease mechanisms, identify drug targets or
biomarkers and explore strategies for repurposing existing drugs.
QIAGEN Biomedical KB-AI provides the most complete picture of
biomedical relationships, including edge cases and novel
relationships.
While QIAGEN Biomedical KB-HD is manually
curated and known for its high quality and accuracy, QIAGEN
Biomedical KB-AI contains over 25x more relationships, allowing
data scientists to generate new insights. Both knowledge bases can
be used to provide both high-quality and high-quantity biomedical
relationships data for data scientists and bioinformaticians to
mine and validate.
“QIAGEN Biomedical KB-AI represents a
significant step forward in our mission to empower biopharma
customers with the most comprehensive and informative molecular
knowledge bases,” said Jonathan Sheldon, Senior Vice President of
QIAGEN Digital Insights. “By combining the strengths of AI and
human curation approaches, we provide researchers with the widest,
deepest and highest quality knowledge sources.”
Key features of QIAGEN Biomedical KB-AI
include:
-
Massive scale: 640 million biomedical relationships curated
from literature, patents, grants and other sources
-
Causality: Over 6.4 million gene causal
relationships, 1.99 million disease causal
relationships and 1.16 million drug causal relationships
-
Structured: Results are structured in an ontology for rapid
querying and advanced analytics
-
Timely: Updated quarterly to capture the most recent
research and discoveries
QIAGEN continuously integrates AI technology in
its QIAGEN Digital Insights portfolio. As recently as September
2023, it released an AI-driven enhancement to its market-leading
QIAGEN Clinical Insight Interpret product capabilities.
To learn more about QIAGEN Biomedical KB-AI
technology, visit:
https://digitalinsights.qiagen.com/biomedical-knowledge-base/
About QIAGEN Digital Insights
QIAGEN Digital Insights, the bioinformatics
business of QIAGEN, is the leading provider of genomic and clinical
knowledge, analysis and interpretation tools and services for
scientists and clinicians. We have over 25 years of experience in
the industry, 90,000 users worldwide, over 100,000 citations in
scientific papers, more than 3.5 million profiled patient cases and
over 40 billion scientific data points. Discover our portfolio of
expertly curated genomic and clinical knowledge solutions as well
as bioinformatics software and services for efficient data
management, sharing and actionable insights.
http://digitalinsights.qiagen.com
About QIAGEN
QIAGEN N.V., a Netherlands-based holding
company, is the leading global provider of Sample to Insight
solutions that enable customers to gain valuable molecular insights
from samples containing the building blocks of life. Our sample
technologies isolate and process DNA, RNA and proteins from blood,
tissue and other materials. Assay technologies make these
biomolecules visible and ready for analysis. Bioinformatics
software and knowledge bases interpret data to report relevant,
actionable insights. Automation solutions tie these together in
seamless and cost-effective workflows. QIAGEN provides solutions to
more than 500,000 customers around the world in Molecular
Diagnostics (human healthcare) and Life Sciences (academia, pharma
R&D and industrial applications, primarily forensics). As of
December 31, 2023, QIAGEN employed approximately 6,000 people
in over 35 locations worldwide. Further information can be found at
http://www.qiagen.com.
Forward-Looking Statement
Certain statements contained in this press
release may be considered forward-looking statements within the
meaning of Section 27A of the U.S. Securities Act of 1933, as
amended, and Section 21E of the U.S. Securities Exchange Act of
1934, as amended. To the extent that any of the statements
contained herein relating to QIAGEN's products, timing for launch
and development, marketing and/or regulatory approvals, financial
and operational outlook, growth and expansion, collaborations,
markets, strategy or operating results, including without
limitation its expected adjusted net sales and adjusted diluted
earnings results, are forward-looking, such statements are based on
current expectations and assumptions that involve a number of
uncertainties and risks. Such uncertainties and risks include, but
are not limited to, risks associated with management of growth and
international operations (including the effects of currency
fluctuations, regulatory processes and dependence on logistics),
variability of operating results and allocations between customer
classes, the commercial development of markets for our products to
customers in academia, pharma, applied testing and molecular
diagnostics; changing relationships with customers, suppliers and
strategic partners; competition; rapid or unexpected changes in
technologies; fluctuations in demand for QIAGEN's products
(including fluctuations due to general economic conditions, the
level and timing of customers' funding, budgets and other factors);
our ability to obtain regulatory approval of our products;
difficulties in successfully adapting QIAGEN's products to
integrated solutions and producing such products; the ability of
QIAGEN to identify and develop new products and to differentiate
and protect our products from competitors' products; market
acceptance of QIAGEN's new products and the integration of acquired
technologies and businesses; actions of governments, global or
regional economic developments, weather or transportation delays,
natural disasters, political or public health crises, and its
impact on the demand for our products and other aspects of our
business, or other force majeure events; as well as the possibility
that expected benefits related to recent or pending acquisitions
may not materialize as expected; and the other factors discussed
under the heading “Risk Factors” contained in Item 3 of our most
recent Annual Report on Form 20-F. For further information, please
refer to the discussions in reports that QIAGEN has filed with, or
furnished to, the U.S. Securities and Exchange
Commission.
John Gilardi
QIAGEN N.V.
+49 2103 29 11711
ir@qiagen.com
Phoebe Loh
QIAGEN N.V.
+49 2103 29 11457
ir@qiagen.com
Thomas Theuringer
QIAGEN N.V.
+49 2103 29 11826
pr@qiagen.com
Daniela Berheide
QIAGEN N.V.
+49 2103 29 11676
pr@qiagen.com
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From Apr 2024 to May 2024
Qiagen NV (NYSE:QGEN)
Historical Stock Chart
From May 2023 to May 2024